Mark R Rigby1, Mario R Ehlers. 1. aIndiana University School of Medicine and Riley Hospital for Children at IU Health, Indianapolis, Indiana bImmune Tolerance Network, San Francisco, California, USA.
Abstract
PURPOSE OF REVIEW: Although insulin is lifesaving and sustaining for those with type 1 diabetes (T1D), curing the disease will be much more complex than simple replacement of this hormone. T1D is an autoimmune disease orchestrated by T cells, and includes many arms of the immune response. Tremendous effort has gone into understanding its underlying immune, genetic, and environmental causes, and this progress has led to immunologically based clinical trials in T1D. This review will focus primarily on the clinical trials of the past decade that have attempted to translate these fundamental findings. RECENT FINDINGS: It is known that powerful, nonspecific immune suppressants can temporarily slow the course of newly diagnosed T1D, yet are too toxic for long-term use, especially in children. Recent clinical trials to reverse T1D have used newly developed therapies that target specific components of the immune process believed to be involved with T1D. Although well justified and designed, no recent approach has resulted in clinical remission and few have had any effect on disease course. SUMMARY: Advances in our fundamental understanding of how the human diabetes immune response is activated and regulated coupled with lessons that have been learnt from the most recent era of completed trials are guiding us toward the development of more effective, multipronged therapies to ablate diabetes autoimmunity, restore immune tolerance, preserve β cells, and, ultimately, improve the lives of patients with T1D.
PURPOSE OF REVIEW: Although insulin is lifesaving and sustaining for those with type 1 diabetes (T1D), curing the disease will be much more complex than simple replacement of this hormone. T1D is an autoimmune disease orchestrated by T cells, and includes many arms of the immune response. Tremendous effort has gone into understanding its underlying immune, genetic, and environmental causes, and this progress has led to immunologically based clinical trials in T1D. This review will focus primarily on the clinical trials of the past decade that have attempted to translate these fundamental findings. RECENT FINDINGS: It is known that powerful, nonspecific immune suppressants can temporarily slow the course of newly diagnosed T1D, yet are too toxic for long-term use, especially in children. Recent clinical trials to reverse T1D have used newly developed therapies that target specific components of the immune process believed to be involved with T1D. Although well justified and designed, no recent approach has resulted in clinical remission and few have had any effect on disease course. SUMMARY: Advances in our fundamental understanding of how the humandiabetes immune response is activated and regulated coupled with lessons that have been learnt from the most recent era of completed trials are guiding us toward the development of more effective, multipronged therapies to ablate diabetes autoimmunity, restore immune tolerance, preserve β cells, and, ultimately, improve the lives of patients with T1D.
Authors: Volkert A L Huurman; Katelijn Decochez; Chantal Mathieu; Irun R Cohen; Bart O Roep Journal: Diabetes Metab Res Rev Date: 2007-05 Impact factor: 4.876
Authors: V A L Huurman; P E van der Meide; G Duinkerken; S Willemen; I R Cohen; D Elias; B O Roep Journal: Clin Exp Immunol Date: 2008-04-16 Impact factor: 4.330
Authors: Chang-yun Hu; Daniel Rodriguez-Pinto; Wei Du; Anupama Ahuja; Octavian Henegariu; F Susan Wong; Mark J Shlomchik; Li Wen Journal: J Clin Invest Date: 2007-12 Impact factor: 14.808
Authors: F Ortis; P Pirot; N Naamane; A Y Kreins; J Rasschaert; F Moore; E Théâtre; C Verhaeghe; N E Magnusson; A Chariot; T F Orntoft; D L Eizirik Journal: Diabetologia Date: 2008-05-08 Impact factor: 10.122
Authors: Shelagh I Dawson; Jinny Willis; Christopher M Florkowski; Russell S Scott Journal: Diabetes Res Clin Pract Date: 2008-03-07 Impact factor: 5.602
Authors: S Alice Long; Jerill Thorpe; Hannah A DeBerg; Vivian Gersuk; James Eddy; Kristina M Harris; Mario Ehlers; Kevan C Herold; Gerald T Nepom; Peter S Linsley Journal: Sci Immunol Date: 2016-11-18
Authors: Karen Cerosaletti; Fariba Barahmand-Pour-Whitman; Junbao Yang; Hannah A DeBerg; Matthew J Dufort; Sara A Murray; Elisabeth Israelsson; Cate Speake; Vivian H Gersuk; James A Eddy; Helena Reijonen; Carla J Greenbaum; William W Kwok; Erik Wambre; Martin Prlic; Raphael Gottardo; Gerald T Nepom; Peter S Linsley Journal: J Immunol Date: 2017-05-31 Impact factor: 5.422
Authors: Gordon C Weir; Mario R Ehlers; Kristina M Harris; Sai Kanaparthi; Alice Long; Deborah Phippard; Lia J Weiner; Brett Jepson; James G McNamara; Maria Koulmanda; Terry B Strom Journal: Pediatr Diabetes Date: 2018-05-07 Impact factor: 4.866